Physician profile
Michael James Drass
NPI 1225144520
$12,113.21
in general payments reported to CMS, 2019-2025
39 companies · $947 in 2025
The $947 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $954 · 2020: $844 · 2021: $1,791 · 2022: $2,562 · 2023: $2,702 · 2024: $2,312 · 2025: $947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,961.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,961.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,805.87 | 2019-2025 | General - Pain Management, Wavewriter Alpha Prime 16, Intracept |
| Abbott Laboratories | $1,969.36 | 2019-2025 | Proclaim, Octrode, Eterna |
| Medtronic, INC. | $1,365.62 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Vanta Adaptivestim |
| Relievant Medsystems, INC. | $1,345.50 | 2021-2023 | Intracept |
| Abbvie INC. | $517.61 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Collegium Pharmaceutical, INC. | $485.57 | 2019-2025 | Xtampza, Belbuca, Nucynta |
| Mml US, INC. | $358.82 | 2023-2025 | Reactiv8 |
| Medtronic USA, INC. | $335.79 | 2019-2020 | |
| Foundation Fusion Solutions, LLC | $271.16 | 2020-2025 | |
| Lundbeck LLC | $229.34 | 2021-2025 | Vyepti |
| Bioventus LLC | $225.99 | 2023-2024 | Stimrouter Implantable Kit, Durolane, Durolane |
| Spr Therapeutics, INC | $219.23 | 2022-2024 | Sprint Pns System |
| Nevro Corp. | $212.81 | 2019-2024 | Senza |
| Vertos Medical, INC. | $201.30 | 2023-2024 | Mild Device Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $164.42 | 2020-2025 | Relistor |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Drass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.